CUT Protocol
Retatrutide R25 Fast Start Pen
Your first month of structured Retatrutide optimization.
Key Attributes
- Triple-receptor mechanism — GLP-1, GIP, and glucagon activation in a single compound
- Precision 0.25 mg per click dosing for careful, guided titration
- Appetite regulation typically established within weeks of initial dosing
- Conservative 25 mg total volume — structured for first-protocol safety
- European-sourced, quality-controlled preparation — delivered to Bangkok and throughout Thailand
Technical Specifications
Biohackr.Labs provides product education, protocol guidance, and private client support. Information on this website is not medical advice and does not replace consultation with a licensed healthcare professional.
What's Included
Premium hard case.
Everything included.
Every Biohackr.Labs pen ships in our premium white hard case — holographic logo, foam-fitted interior. Inside: the precision pen, ten individually sealed 31G 8mm micro needles, and all documentation needed to begin your protocol correctly.
Precision pen
Pre-filled, batch quality-controlled pen system ready at your confirmed starting dose.
10× 31G micro needles
31G 8mm individually sealed sterile micro needles. Ten included as standard with every pen.
Protocol card
Starting dose, titration schedule, session guidance, and what to expect — specific to your protocol.
Batch QC documentation
Batch reference, preparation date, and compound specification. Not boilerplate — specific to your order.
Storage & handling guide
Temperature requirements, travel guidance, and handling notes with Bangkok climate context.
Private support access
WhatsApp, LINE, email, and My Account support throughout your protocol cycle.
Professional Packing
Strictly packed for
cold-chain delivery.
Peptide pen formulations are temperature-sensitive. Every order is packed as a refrigerated product and handled under strict cold-chain conditions — insulated temperature-control packaging with cold packs maintained at the standard refrigerated range of 2–8°C wherever available during transit.
Refrigerated cold-chain transport
Peptide pens are handled as refrigerated products throughout transit. Intended transport condition is controlled cold-chain delivery at 2–8°C wherever available. Available in supported cold-chain delivery areas only.
Temperature-control packaging
Insulated temperature-control packaging with cold packs engineered to maintain the product in the refrigerated range from preparation to handover — anywhere in Thailand with cold-chain delivery coverage.
Refrigerate immediately on receipt
Transfer to refrigerated storage the moment you receive your order. Do not leave unattended or delay collection. Tamper-evident sealing confirms product integrity at handover.
Step 01
Protocol Overview
“Your first month of structured Retatrutide optimization.”
The R25 Fast Start Pen delivers 25 mg of Retatrutide across a 4-week guided onboarding protocol. As the most advanced triple-receptor agonist currently in active research — targeting GLP-1, GIP, and glucagon receptors simultaneously — Retatrutide represents a significant advance beyond earlier GLP-1 compounds. The R25 is specifically designed for clients beginning their first Retatrutide protocol, with a conservative total volume that supports careful titration and response tracking without excess.
Step 02
Mechanism of Action
Retatrutide activates three receptors involved in metabolic regulation: GLP-1 (appetite and insulin response), GIP (nutrient partitioning and fat metabolism), and glucagon (energy expenditure and hepatic glucose output). This triple-receptor activity produces a compounding metabolic effect beyond what single or dual-receptor compounds achieve. At the 0.25 mg per click precision of the R25 pen, clients can titrate carefully from an initial low dose toward their individual response threshold.
Suggested Use
One weekly subcutaneous administration. Begin at 0.25 mg (1 click) in week one. Titrate as guided through order review. Not for use without protocol guidance.
Who This Protocol Is For
Designed for clients beginning their first Retatrutide protocol in Bangkok or Thailand seeking a structured, cautious entry point with close response monitoring. Ideal for those transitioning from lifestyle approaches or earlier GLP-1 compounds.
Storage — Bangkok & Thailand
Store refrigerated between 2–8°C. In Bangkok and Thailand's tropical climate, refrigerated storage is essential. Do not leave in heat, direct sunlight, or unrefrigerated vehicles. Suitable for travel with a cold pack for journeys under 4 hours.
Delivery — Thailand
Peptide pens are shipped under strict cold-chain handling — handled as refrigerated products at 2–8°C wherever available. Available in supported cold-chain delivery areas only.
Refrigerate immediately on receipt. You must be present to receive the delivery directly.
Potential Side Effects
- GI effects (nausea, vomiting, diarrhoea) — most common; dose-dependent and typically improve with careful titration
- Reduced appetite — expected mechanism effect; can be significant at therapeutic doses
- Injection site reactions — transient redness or discomfort at administration site
- Fatigue — reported during dose escalation phases
- Dysesthesia (tingling or altered skin sensation) — observed in approximately 21% of participants at 12 mg in Phase 3 trial data
- Cardiac effects under active investigation in ongoing Phase 3 trials — prior medical suitability review required
Science Hub
Order Review Required
All Biohackr.Labs orders are reviewed before confirmation. Dosing and administration are confirmed before fulfilment where required.
Enquire on WhatsAppAdd LINEThe Compound
What Is Retatrutide?
Retatrutide (LY3437943) is a synthetic once-weekly peptide developed by Eli Lilly — the first triple hormone receptor agonist to enter Phase 3 clinical trials. Where semaglutide activates one receptor and tirzepatide activates two, retatrutide simultaneously activates three: GLP-1, GIP, and glucagon. This triple mechanism produces compounding effects on appetite, fat metabolism, and energy expenditure that neither dual nor single agonists can replicate.
By targeting three complementary metabolic pathways at once, retatrutide addresses the biology of excess weight from multiple angles simultaneously. The result is weight loss outcomes that exceed what single or dual agonist compounds can achieve — including outcomes comparable to bariatric surgery in a subset of patients.
Semaglutide
Ozempic / Wegovy
Mechanism
GLP-1 only
Peak weight loss
~13.9%
Tirzepatide
Mounjaro / Zepbound
Mechanism
GLP-1 + GIP
Peak weight loss
~17.8–20.9%
Retatrutide
Pending (LY3437943)
Mechanism
GLP-1 + GIP + Glucagon
Peak weight loss
~28.3–30.3%
Cross-trial comparisons have inherent limitations. A head-to-head trial would be required for definitive conclusions.
Triple Mechanism
What Each Agonist Does
GLP-1
Glucagon-Like Peptide-1
Role
Appetite and insulin regulation
Slows gastric emptying to reduce caloric intake, suppresses appetite signals in the hypothalamus, and stimulates glucose-dependent insulin secretion. GLP-1 agonism is the foundation of semaglutide and tirzepatide — and the primary mechanism of all incretin-based compounds.
Key Effect
Appetite reduction + insulin sensitivity
Also in: Semaglutide, Tirzepatide
GIP
Glucose-dependent Insulinotropic Polypeptide
Role
Nutrient partitioning and fat cell metabolism
Enhances insulin sensitivity in peripheral tissues, modulates how the body partitions incoming calories between storage and use, and appears to amplify the appetite-suppressing effects of GLP-1 agonism. GIP is the second receptor targeted by tirzepatide — and a key contributor to its weight loss advantage over semaglutide.
Key Effect
Enhanced insulin sensitivity + fat cell regulation
Also in: Tirzepatide
Glucagon
Glucagon Receptor
Role
Energy expenditure and direct liver fat clearance
The critical differentiator. Glucagon receptor activation directly stimulates the liver to burn stored fat (fatty acid oxidation) and suppresses new fat synthesis (de novo lipogenesis). It also increases basal metabolic rate and thermogenesis — meaning the body burns more calories at rest. No approved obesity medication targets this receptor. It is the mechanism responsible for retatrutide's unprecedented liver fat reduction data.
Key Effect
Increased energy expenditure + hepatic fat clearance
Also in: Unique to Retatrutide among approved/late-stage compounds
Beyond Weight Loss
Emerging Benefits From Clinical Data
Clinical trial data surfacing across the TRIUMPH program suggests retatrutide may offer systemic benefits beyond weight management — driven by the glucagon receptor component that neither semaglutide nor tirzepatide possess.
Metabolic Liver Disease (MASLD/MASH)
The glucagon receptor component drives direct hepatic fat oxidation — the liver burns its stored triglycerides. Phase 2a data (Nature Medicine, 2024) showed 82.4% liver fat reduction and more than 85% liver fat normalization at the 12 mg dose. Phase 3 MASLD/MASH-specific trials are underway.
Knee Osteoarthritis
TRIUMPH-1 reported a nested knee osteoarthritis basket trial, with WOMAC pain scores reduced by up to 4.3 points (73.1%) at 80 weeks. TRIUMPH-4 remains the dedicated knee osteoarthritis study in the registry.
Systemic Inflammation
TRIUMPH-1 investigators noted "clear improvements in assessed cardiometabolic health measures" including inflammatory markers. The triple receptor mechanism appears to address metabolic inflammation through multiple pathways — weight-independent of the pure weight loss effect.
Insulin Resistance
TRIUMPH-2 topline data in adults with type 2 diabetes and obesity or overweight reported up to 20.8% mean weight loss and A1C reductions of up to 1.6 percentage points over 80 weeks.
Sleep Apnoea
TRIUMPH-1 reported a nested moderate-to-severe obstructive sleep apnoea basket trial, with apnea-hypopnea index reduced by up to 36.1 events per hour (60.6%) at 80 weeks.
Cardiovascular Outcomes
TRIUMPH-3 reported up to 22.6% mean weight loss at 80 weeks in adults with severe obesity and established cardiovascular disease. Its pre-specified cardiovascular event analyses were underpowered and inconclusive, so the dedicated TRIUMPH-Outcomes study remains the key cardiovascular and kidney outcomes trial.
All emerging benefit data is from Phase 2 or Phase 3 clinical trial publications and official Eli Lilly announcements. Retatrutide is investigational. Benefits described are not confirmed clinical indications.
Live Research
TRIUMPH Trial Tracker
Last updated
July 26, 2026
Eli Lilly TRIUMPH Phase 3 · published highlights + active registry watch
28.3% avg weight loss at 80 weeks (12 mg). 30.3% at 104 weeks in the BMI >=35 extension. 45.3% lost >30% bodyweight.
Topline Lilly readout: up to 20.8% mean weight loss at 80 weeks and A1C reductions up to 1.6 percentage points; detailed peer-reviewed results pending.
Topline Lilly readout: up to 22.6% mean weight loss at 80 weeks; cardiovascular event analyses were inconclusive because event rates were lower than expected.
28.7% avg weight loss at 68 weeks (12 mg). Substantial knee pain reduction.
Large event-driven Phase 3 outcomes study; ClinicalTrials.gov lists estimated completion in 2029.
Lilly plans to submit a Biologics License Application for U.S. approval in Q1 2027. · ClinicalTrials.gov API checked July 26, 2026. Review monthly, and immediately after Lilly readouts or registry updates. Data is reviewed against official registries, Eli Lilly releases, and peer-reviewed publications. Retatrutide is investigational and not approved for clinical use.
Key Statistics
Phase 3 TRIUMPH Data Highlights
30.3%
Average weight loss at 104 weeks
12 mg dose, TRIUMPH-1 — comparable to bariatric surgery outcomes
Eli Lilly, June 2026
45.3%
Patients losing >30% body weight
12 mg dose — a threshold historically achievable only through surgery
TRIUMPH-1, June 2026
70.3 lbs
Average weight lost at 80 weeks
12 mg dose, TRIUMPH-1 — highest weight loss for any non-surgical intervention in Phase 3
Eli Lilly, June 2026
82.4%
Liver fat reduction at 48 weeks
12 mg dose, Phase 2a liver sub-study — unprecedented for any pharmacological compound
Nature Medicine, 2024
>85%
Patients achieving normal liver fat levels
<5% liver fat at the 12 mg dose after 24 and 48 weeks
Nature Medicine, 2024
5,800+
Participants enrolled in TRIUMPH program
Across four global registrational trials — the largest retatrutide trial program to date
Eli Lilly, 2026
Same Collection
Related CUT Protocols
My Account
Premium imported peptide pens in Bangkok.
Reviewed My Account ordering · European-sourced · Quality-controlled · Thailand delivery
Enquire About Retatrutide R25 Fast Start Pen